nodes	percent_of_prediction	percent_of_DWPC	metapath
Dipivefrin—ACHE—Irinotecan—hematologic cancer	0.173	0.346	CbGbCtD
Dipivefrin—BCHE—Triamcinolone—hematologic cancer	0.137	0.275	CbGbCtD
Dipivefrin—BCHE—Irinotecan—hematologic cancer	0.104	0.209	CbGbCtD
Dipivefrin—BCHE—Cisplatin—hematologic cancer	0.0848	0.17	CbGbCtD
Dipivefrin—Stinging—Alitretinoin—hematologic cancer	0.0033	0.0132	CcSEcCtD
Dipivefrin—Conjunctivitis—Daunorubicin—hematologic cancer	0.0028	0.0112	CcSEcCtD
Dipivefrin—Conjunctivitis—Pentostatin—hematologic cancer	0.00278	0.0111	CcSEcCtD
Dipivefrin—Conjunctivitis—Anagrelide—hematologic cancer	0.00278	0.0111	CcSEcCtD
Dipivefrin—Mydriasis—Prednisolone—hematologic cancer	0.00258	0.0103	CcSEcCtD
Dipivefrin—Stinging—Prednisolone—hematologic cancer	0.00254	0.0101	CcSEcCtD
Dipivefrin—Arrhythmia—Methoxsalen—hematologic cancer	0.00241	0.0096	CcSEcCtD
Dipivefrin—Stinging—Triamcinolone—hematologic cancer	0.00234	0.00933	CcSEcCtD
Dipivefrin—Arrhythmia—Daunorubicin—hematologic cancer	0.00231	0.0092	CcSEcCtD
Dipivefrin—Conjunctivitis—Bexarotene—hematologic cancer	0.0023	0.00918	CcSEcCtD
Dipivefrin—Conjunctivitis—Dasatinib—hematologic cancer	0.0023	0.00918	CcSEcCtD
Dipivefrin—Arrhythmia—Anagrelide—hematologic cancer	0.0023	0.00916	CcSEcCtD
Dipivefrin—Arrhythmia—Pentostatin—hematologic cancer	0.0023	0.00916	CcSEcCtD
Dipivefrin—Arrhythmia—Idarubicin—hematologic cancer	0.00222	0.00883	CcSEcCtD
Dipivefrin—Arrhythmia—Teniposide—hematologic cancer	0.00216	0.00859	CcSEcCtD
Dipivefrin—Conjunctivitis—Nilotinib—hematologic cancer	0.00213	0.00848	CcSEcCtD
Dipivefrin—Stinging—Betamethasone—hematologic cancer	0.00212	0.00846	CcSEcCtD
Dipivefrin—Stinging—Dexamethasone—hematologic cancer	0.00212	0.00846	CcSEcCtD
Dipivefrin—Conjunctivitis—Imatinib—hematologic cancer	0.00211	0.00843	CcSEcCtD
Dipivefrin—Conjunctivitis—Cladribine—hematologic cancer	0.00208	0.00829	CcSEcCtD
Dipivefrin—Arrhythmia—Busulfan—hematologic cancer	0.002	0.00796	CcSEcCtD
Dipivefrin—Hypertension—Clofarabine—hematologic cancer	0.00194	0.00774	CcSEcCtD
Dipivefrin—Hypertension—Daunorubicin—hematologic cancer	0.00194	0.00774	CcSEcCtD
Dipivefrin—Arrhythmia—Procarbazine—hematologic cancer	0.00194	0.00773	CcSEcCtD
Dipivefrin—Hypertension—Pentostatin—hematologic cancer	0.00193	0.00771	CcSEcCtD
Dipivefrin—Hypertension—Anagrelide—hematologic cancer	0.00193	0.00771	CcSEcCtD
Dipivefrin—Arrhythmia—Bexarotene—hematologic cancer	0.0019	0.00757	CcSEcCtD
Dipivefrin—Arrhythmia—Dasatinib—hematologic cancer	0.0019	0.00757	CcSEcCtD
Dipivefrin—Arrhythmia—Fludarabine—hematologic cancer	0.00189	0.00755	CcSEcCtD
Dipivefrin—Conjunctivitis—Lenalidomide—hematologic cancer	0.00184	0.00735	CcSEcCtD
Dipivefrin—Hypertension—Teniposide—hematologic cancer	0.00181	0.00723	CcSEcCtD
Dipivefrin—Tachycardia—Daunorubicin—hematologic cancer	0.00179	0.00714	CcSEcCtD
Dipivefrin—Tachycardia—Clofarabine—hematologic cancer	0.00179	0.00714	CcSEcCtD
Dipivefrin—Tachycardia—Anagrelide—hematologic cancer	0.00178	0.00711	CcSEcCtD
Dipivefrin—Tachycardia—Pentostatin—hematologic cancer	0.00178	0.00711	CcSEcCtD
Dipivefrin—Arrhythmia—Nilotinib—hematologic cancer	0.00175	0.007	CcSEcCtD
Dipivefrin—Arrhythmia—Imatinib—hematologic cancer	0.00174	0.00696	CcSEcCtD
Dipivefrin—Arrhythmia—Cladribine—hematologic cancer	0.00171	0.00684	CcSEcCtD
Dipivefrin—Hypersensitivity—Mechlorethamine—hematologic cancer	0.00171	0.00683	CcSEcCtD
Dipivefrin—Conjunctivitis—Bortezomib—hematologic cancer	0.0017	0.00676	CcSEcCtD
Dipivefrin—Hypertension—Busulfan—hematologic cancer	0.00168	0.0067	CcSEcCtD
Dipivefrin—Pain—Nelarabine—hematologic cancer	0.00168	0.00669	CcSEcCtD
Dipivefrin—Tachycardia—Teniposide—hematologic cancer	0.00167	0.00667	CcSEcCtD
Dipivefrin—Hypertension—Procarbazine—hematologic cancer	0.00163	0.0065	CcSEcCtD
Dipivefrin—Hypertension—Dasatinib—hematologic cancer	0.0016	0.00637	CcSEcCtD
Dipivefrin—Hypertension—Bexarotene—hematologic cancer	0.0016	0.00637	CcSEcCtD
Dipivefrin—Conjunctivitis—Thiotepa—hematologic cancer	0.00158	0.00631	CcSEcCtD
Dipivefrin—Pain—Daunorubicin—hematologic cancer	0.00157	0.00626	CcSEcCtD
Dipivefrin—Pain—Clofarabine—hematologic cancer	0.00157	0.00626	CcSEcCtD
Dipivefrin—Arrhythmia—Melphalan—hematologic cancer	0.00156	0.00624	CcSEcCtD
Dipivefrin—Pain—Anagrelide—hematologic cancer	0.00156	0.00623	CcSEcCtD
Dipivefrin—Pain—Pentostatin—hematologic cancer	0.00156	0.00623	CcSEcCtD
Dipivefrin—Tachycardia—Busulfan—hematologic cancer	0.00155	0.00618	CcSEcCtD
Dipivefrin—Conjunctivitis—Thalidomide—hematologic cancer	0.00153	0.0061	CcSEcCtD
Dipivefrin—Arrhythmia—Lenalidomide—hematologic cancer	0.00152	0.00606	CcSEcCtD
Dipivefrin—Tachycardia—Procarbazine—hematologic cancer	0.0015	0.006	CcSEcCtD
Dipivefrin—Hypertension—Nilotinib—hematologic cancer	0.00148	0.00589	CcSEcCtD
Dipivefrin—Tachycardia—Dasatinib—hematologic cancer	0.00147	0.00588	CcSEcCtD
Dipivefrin—Tachycardia—Bexarotene—hematologic cancer	0.00147	0.00588	CcSEcCtD
Dipivefrin—Hypertension—Imatinib—hematologic cancer	0.00147	0.00585	CcSEcCtD
Dipivefrin—Conjunctivitis—Alitretinoin—hematologic cancer	0.00146	0.0058	CcSEcCtD
Dipivefrin—Stinging—Epirubicin—hematologic cancer	0.00145	0.00576	CcSEcCtD
Dipivefrin—Conjunctivitis—Ifosfamide—hematologic cancer	0.00144	0.00574	CcSEcCtD
Dipivefrin—Hypersensitivity—Methoxsalen—hematologic cancer	0.00141	0.00563	CcSEcCtD
Dipivefrin—Arrhythmia—Bortezomib—hematologic cancer	0.0014	0.00558	CcSEcCtD
Dipivefrin—Hypertension—Vinblastine—hematologic cancer	0.00138	0.00552	CcSEcCtD
Dipivefrin—Hypersensitivity—Mercaptopurine—hematologic cancer	0.00137	0.00547	CcSEcCtD
Dipivefrin—Arrhythmia—Vinorelbine—hematologic cancer	0.00137	0.00545	CcSEcCtD
Dipivefrin—Conjunctivitis—Mitoxantrone—hematologic cancer	0.00137	0.00545	CcSEcCtD
Dipivefrin—Tachycardia—Nilotinib—hematologic cancer	0.00136	0.00543	CcSEcCtD
Dipivefrin—Pain—Busulfan—hematologic cancer	0.00136	0.00542	CcSEcCtD
Dipivefrin—Tachycardia—Imatinib—hematologic cancer	0.00135	0.0054	CcSEcCtD
Dipivefrin—Hypersensitivity—Clofarabine—hematologic cancer	0.00135	0.00539	CcSEcCtD
Dipivefrin—Hypersensitivity—Daunorubicin—hematologic cancer	0.00135	0.00539	CcSEcCtD
Dipivefrin—Hypersensitivity—Pentostatin—hematologic cancer	0.00135	0.00537	CcSEcCtD
Dipivefrin—Stinging—Doxorubicin—hematologic cancer	0.00134	0.00533	CcSEcCtD
Dipivefrin—Tachycardia—Cladribine—hematologic cancer	0.00133	0.00531	CcSEcCtD
Dipivefrin—Pain—Procarbazine—hematologic cancer	0.00132	0.00525	CcSEcCtD
Dipivefrin—Arrhythmia—Thiotepa—hematologic cancer	0.0013	0.0052	CcSEcCtD
Dipivefrin—Hypersensitivity—Idarubicin—hematologic cancer	0.0013	0.00518	CcSEcCtD
Dipivefrin—Pain—Dasatinib—hematologic cancer	0.00129	0.00515	CcSEcCtD
Dipivefrin—Pain—Bexarotene—hematologic cancer	0.00129	0.00515	CcSEcCtD
Dipivefrin—Pain—Fludarabine—hematologic cancer	0.00129	0.00514	CcSEcCtD
Dipivefrin—Hypertension—Lenalidomide—hematologic cancer	0.00128	0.0051	CcSEcCtD
Dipivefrin—Hypersensitivity—Teniposide—hematologic cancer	0.00126	0.00503	CcSEcCtD
Dipivefrin—Arrhythmia—Thalidomide—hematologic cancer	0.00126	0.00503	CcSEcCtD
Dipivefrin—Conjunctivitis—Cisplatin—hematologic cancer	0.00124	0.00494	CcSEcCtD
Dipivefrin—Pain—Chlorambucil—hematologic cancer	0.00122	0.00487	CcSEcCtD
Dipivefrin—Tachycardia—Melphalan—hematologic cancer	0.00121	0.00484	CcSEcCtD
Dipivefrin—Arrhythmia—Carmustine—hematologic cancer	0.00121	0.00483	CcSEcCtD
Dipivefrin—Epinephrine—SLC22A1—hematologic cancer	0.0012	0.581	CrCbGaD
Dipivefrin—Arrhythmia—Alitretinoin—hematologic cancer	0.0012	0.00479	CcSEcCtD
Dipivefrin—Pain—Nilotinib—hematologic cancer	0.00119	0.00476	CcSEcCtD
Dipivefrin—Arrhythmia—Ifosfamide—hematologic cancer	0.00119	0.00473	CcSEcCtD
Dipivefrin—Pain—Imatinib—hematologic cancer	0.00119	0.00473	CcSEcCtD
Dipivefrin—Tachycardia—Lenalidomide—hematologic cancer	0.00118	0.00471	CcSEcCtD
Dipivefrin—Hypertension—Bortezomib—hematologic cancer	0.00118	0.00469	CcSEcCtD
Dipivefrin—Hypersensitivity—Busulfan—hematologic cancer	0.00117	0.00467	CcSEcCtD
Dipivefrin—Pain—Cladribine—hematologic cancer	0.00117	0.00465	CcSEcCtD
Dipivefrin—Hypertension—Vinorelbine—hematologic cancer	0.00115	0.00458	CcSEcCtD
Dipivefrin—Hypersensitivity—Procarbazine—hematologic cancer	0.00114	0.00453	CcSEcCtD
Dipivefrin—Arrhythmia—Mitoxantrone—hematologic cancer	0.00113	0.00449	CcSEcCtD
Dipivefrin—Arrhythmia—Irinotecan—hematologic cancer	0.00113	0.00449	CcSEcCtD
Dipivefrin—Conjunctivitis—Prednisolone—hematologic cancer	0.00112	0.00447	CcSEcCtD
Dipivefrin—Pain—Vinblastine—hematologic cancer	0.00112	0.00446	CcSEcCtD
Dipivefrin—Hypersensitivity—Dasatinib—hematologic cancer	0.00111	0.00444	CcSEcCtD
Dipivefrin—Hypersensitivity—Bexarotene—hematologic cancer	0.00111	0.00444	CcSEcCtD
Dipivefrin—Hypersensitivity—Fludarabine—hematologic cancer	0.00111	0.00442	CcSEcCtD
Dipivefrin—Hypertension—Thiotepa—hematologic cancer	0.0011	0.00438	CcSEcCtD
Dipivefrin—Arrhythmia—Gemcitabine—hematologic cancer	0.0011	0.00438	CcSEcCtD
Dipivefrin—Tachycardia—Bortezomib—hematologic cancer	0.00109	0.00433	CcSEcCtD
Dipivefrin—Pain—Melphalan—hematologic cancer	0.00106	0.00424	CcSEcCtD
Dipivefrin—Hypertension—Thalidomide—hematologic cancer	0.00106	0.00423	CcSEcCtD
Dipivefrin—Tachycardia—Vinorelbine—hematologic cancer	0.00106	0.00423	CcSEcCtD
Dipivefrin—Hypersensitivity—Chlorambucil—hematologic cancer	0.00105	0.00419	CcSEcCtD
Dipivefrin—Pain—Lenalidomide—hematologic cancer	0.00103	0.00412	CcSEcCtD
Dipivefrin—Conjunctivitis—Triamcinolone—hematologic cancer	0.00103	0.00411	CcSEcCtD
Dipivefrin—Hypersensitivity—Nilotinib—hematologic cancer	0.00103	0.0041	CcSEcCtD
Dipivefrin—Arrhythmia—Cisplatin—hematologic cancer	0.00102	0.00408	CcSEcCtD
Dipivefrin—Hypersensitivity—Imatinib—hematologic cancer	0.00102	0.00408	CcSEcCtD
Dipivefrin—Hypertension—Carmustine—hematologic cancer	0.00102	0.00407	CcSEcCtD
Dipivefrin—Pain—Hydroxyurea—hematologic cancer	0.00102	0.00407	CcSEcCtD
Dipivefrin—Tachycardia—Thiotepa—hematologic cancer	0.00101	0.00404	CcSEcCtD
Dipivefrin—Hypertension—Alitretinoin—hematologic cancer	0.00101	0.00403	CcSEcCtD
Dipivefrin—Hypersensitivity—Cladribine—hematologic cancer	0.001	0.00401	CcSEcCtD
Dipivefrin—Hypertension—Ifosfamide—hematologic cancer	0.000998	0.00398	CcSEcCtD
Dipivefrin—Tachycardia—Thalidomide—hematologic cancer	0.00098	0.00391	CcSEcCtD
Dipivefrin—Hypertension—Vincristine—hematologic cancer	0.000974	0.00388	CcSEcCtD
Dipivefrin—Hypersensitivity—Vinblastine—hematologic cancer	0.000963	0.00384	CcSEcCtD
Dipivefrin—Pain—Bortezomib—hematologic cancer	0.000952	0.00379	CcSEcCtD
Dipivefrin—Hypertension—Irinotecan—hematologic cancer	0.000948	0.00378	CcSEcCtD
Dipivefrin—Hypertension—Mitoxantrone—hematologic cancer	0.000948	0.00378	CcSEcCtD
Dipivefrin—Pain—Bleomycin—hematologic cancer	0.000944	0.00377	CcSEcCtD
Dipivefrin—Tachycardia—Carmustine—hematologic cancer	0.000941	0.00375	CcSEcCtD
Dipivefrin—Conjunctivitis—Dexamethasone—hematologic cancer	0.000935	0.00373	CcSEcCtD
Dipivefrin—Conjunctivitis—Betamethasone—hematologic cancer	0.000935	0.00373	CcSEcCtD
Dipivefrin—Tachycardia—Alitretinoin—hematologic cancer	0.000932	0.00372	CcSEcCtD
Dipivefrin—Pain—Vinorelbine—hematologic cancer	0.000929	0.00371	CcSEcCtD
Dipivefrin—Arrhythmia—Prednisolone—hematologic cancer	0.000925	0.00369	CcSEcCtD
Dipivefrin—Hypertension—Gemcitabine—hematologic cancer	0.000924	0.00368	CcSEcCtD
Dipivefrin—Hypersensitivity—Melphalan—hematologic cancer	0.000916	0.00365	CcSEcCtD
Dipivefrin—Hypersensitivity—Lenalidomide—hematologic cancer	0.000891	0.00355	CcSEcCtD
Dipivefrin—Pain—Thiotepa—hematologic cancer	0.000887	0.00354	CcSEcCtD
Dipivefrin—Hypersensitivity—Hydroxyurea—hematologic cancer	0.000879	0.0035	CcSEcCtD
Dipivefrin—Tachycardia—Mitoxantrone—hematologic cancer	0.000875	0.00349	CcSEcCtD
Dipivefrin—Epinephrine—TNF—hematologic cancer	0.000867	0.418	CrCbGaD
Dipivefrin—Pain—Thalidomide—hematologic cancer	0.000858	0.00342	CcSEcCtD
Dipivefrin—Arrhythmia—Triamcinolone—hematologic cancer	0.00085	0.00339	CcSEcCtD
Dipivefrin—Pain—Carmustine—hematologic cancer	0.000824	0.00329	CcSEcCtD
Dipivefrin—Hypersensitivity—Bortezomib—hematologic cancer	0.00082	0.00327	CcSEcCtD
Dipivefrin—Pain—Alitretinoin—hematologic cancer	0.000817	0.00326	CcSEcCtD
Dipivefrin—Hypersensitivity—Bleomycin—hematologic cancer	0.000814	0.00324	CcSEcCtD
Dipivefrin—Pain—Ifosfamide—hematologic cancer	0.000807	0.00322	CcSEcCtD
Dipivefrin—Hypersensitivity—Vinorelbine—hematologic cancer	0.000801	0.00319	CcSEcCtD
Dipivefrin—Tachycardia—Cisplatin—hematologic cancer	0.000794	0.00317	CcSEcCtD
Dipivefrin—Hypertension—Etoposide—hematologic cancer	0.000789	0.00314	CcSEcCtD
Dipivefrin—Pain—Vincristine—hematologic cancer	0.000787	0.00314	CcSEcCtD
Dipivefrin—Hypertension—Prednisolone—hematologic cancer	0.000778	0.0031	CcSEcCtD
Dipivefrin—Arrhythmia—Dexamethasone—hematologic cancer	0.000771	0.00308	CcSEcCtD
Dipivefrin—Arrhythmia—Betamethasone—hematologic cancer	0.000771	0.00308	CcSEcCtD
Dipivefrin—Pain—Irinotecan—hematologic cancer	0.000766	0.00306	CcSEcCtD
Dipivefrin—Pain—Mitoxantrone—hematologic cancer	0.000766	0.00306	CcSEcCtD
Dipivefrin—Hypersensitivity—Thiotepa—hematologic cancer	0.000765	0.00305	CcSEcCtD
Dipivefrin—Pain—Gemcitabine—hematologic cancer	0.000747	0.00298	CcSEcCtD
Dipivefrin—Hypersensitivity—Thalidomide—hematologic cancer	0.00074	0.00295	CcSEcCtD
Dipivefrin—Tachycardia—Etoposide—hematologic cancer	0.000728	0.0029	CcSEcCtD
Dipivefrin—Tachycardia—Prednisolone—hematologic cancer	0.000718	0.00286	CcSEcCtD
Dipivefrin—Hypertension—Triamcinolone—hematologic cancer	0.000715	0.00285	CcSEcCtD
Dipivefrin—Hypersensitivity—Carmustine—hematologic cancer	0.00071	0.00283	CcSEcCtD
Dipivefrin—Hypersensitivity—Alitretinoin—hematologic cancer	0.000704	0.00281	CcSEcCtD
Dipivefrin—Pain—Cisplatin—hematologic cancer	0.000696	0.00277	CcSEcCtD
Dipivefrin—Hypersensitivity—Ifosfamide—hematologic cancer	0.000695	0.00277	CcSEcCtD
Dipivefrin—Conjunctivitis—Methotrexate—hematologic cancer	0.000681	0.00271	CcSEcCtD
Dipivefrin—Hypersensitivity—Vincristine—hematologic cancer	0.000678	0.0027	CcSEcCtD
Dipivefrin—Arrhythmia—Prednisone—hematologic cancer	0.000672	0.00268	CcSEcCtD
Dipivefrin—Hypersensitivity—Irinotecan—hematologic cancer	0.00066	0.00263	CcSEcCtD
Dipivefrin—Hypersensitivity—Mitoxantrone—hematologic cancer	0.00066	0.00263	CcSEcCtD
Dipivefrin—Tachycardia—Triamcinolone—hematologic cancer	0.00066	0.00263	CcSEcCtD
Dipivefrin—Hypertension—Betamethasone—hematologic cancer	0.000649	0.00259	CcSEcCtD
Dipivefrin—Hypertension—Dexamethasone—hematologic cancer	0.000649	0.00259	CcSEcCtD
Dipivefrin—Pain—Etoposide—hematologic cancer	0.000637	0.00254	CcSEcCtD
Dipivefrin—Conjunctivitis—Epirubicin—hematologic cancer	0.000637	0.00254	CcSEcCtD
Dipivefrin—Pain—Prednisolone—hematologic cancer	0.000629	0.00251	CcSEcCtD
Dipivefrin—Hypersensitivity—Cisplatin—hematologic cancer	0.0006	0.00239	CcSEcCtD
Dipivefrin—Tachycardia—Dexamethasone—hematologic cancer	0.000599	0.00239	CcSEcCtD
Dipivefrin—Tachycardia—Betamethasone—hematologic cancer	0.000599	0.00239	CcSEcCtD
Dipivefrin—Conjunctivitis—Doxorubicin—hematologic cancer	0.000589	0.00235	CcSEcCtD
Dipivefrin—Pain—Triamcinolone—hematologic cancer	0.000578	0.00231	CcSEcCtD
Dipivefrin—Hypertension—Prednisone—hematologic cancer	0.000565	0.00225	CcSEcCtD
Dipivefrin—Hypersensitivity—Etoposide—hematologic cancer	0.000549	0.00219	CcSEcCtD
Dipivefrin—Hypersensitivity—Prednisolone—hematologic cancer	0.000542	0.00216	CcSEcCtD
Dipivefrin—Arrhythmia—Epirubicin—hematologic cancer	0.000525	0.0021	CcSEcCtD
Dipivefrin—Pain—Betamethasone—hematologic cancer	0.000525	0.00209	CcSEcCtD
Dipivefrin—Pain—Dexamethasone—hematologic cancer	0.000525	0.00209	CcSEcCtD
Dipivefrin—Tachycardia—Prednisone—hematologic cancer	0.000521	0.00208	CcSEcCtD
Dipivefrin—Hypersensitivity—Triamcinolone—hematologic cancer	0.000498	0.00199	CcSEcCtD
Dipivefrin—Arrhythmia—Doxorubicin—hematologic cancer	0.000486	0.00194	CcSEcCtD
Dipivefrin—Hypertension—Epirubicin—hematologic cancer	0.000442	0.00176	CcSEcCtD
Dipivefrin—Hypertension—Doxorubicin—hematologic cancer	0.000409	0.00163	CcSEcCtD
Dipivefrin—Tachycardia—Epirubicin—hematologic cancer	0.000408	0.00163	CcSEcCtD
Dipivefrin—Hypersensitivity—Prednisone—hematologic cancer	0.000394	0.00157	CcSEcCtD
Dipivefrin—Pain—Methotrexate—hematologic cancer	0.000382	0.00152	CcSEcCtD
Dipivefrin—Tachycardia—Doxorubicin—hematologic cancer	0.000377	0.0015	CcSEcCtD
Dipivefrin—Pain—Epirubicin—hematologic cancer	0.000357	0.00142	CcSEcCtD
Dipivefrin—Pain—Doxorubicin—hematologic cancer	0.000331	0.00132	CcSEcCtD
Dipivefrin—Hypersensitivity—Methotrexate—hematologic cancer	0.000329	0.00131	CcSEcCtD
Dipivefrin—Hypersensitivity—Epirubicin—hematologic cancer	0.000308	0.00123	CcSEcCtD
Dipivefrin—Hypersensitivity—Doxorubicin—hematologic cancer	0.000285	0.00114	CcSEcCtD
Dipivefrin—ADRA2C—Signaling by GPCR—MAPK3—hematologic cancer	1.46e-05	5.89e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—FGFR3—hematologic cancer	1.45e-05	5.85e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—CREB1—hematologic cancer	1.45e-05	5.85e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—MAP2K1—hematologic cancer	1.45e-05	5.82e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—MAPK14—hematologic cancer	1.44e-05	5.79e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—PIK3CD—hematologic cancer	1.44e-05	5.78e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—PDGFB—hematologic cancer	1.44e-05	5.78e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—BRAF—hematologic cancer	1.43e-05	5.78e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—MAP2K1—hematologic cancer	1.43e-05	5.75e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—GPCR downstream signaling—PIK3CA—hematologic cancer	1.42e-05	5.73e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—CCL2—hematologic cancer	1.42e-05	5.72e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—PIK3CD—hematologic cancer	1.42e-05	5.71e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—IL6R—hematologic cancer	1.42e-05	5.71e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—CREBBP—hematologic cancer	1.42e-05	5.7e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—ESR1—hematologic cancer	1.41e-05	5.68e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling by GPCR—KRAS—hematologic cancer	1.41e-05	5.66e-05	CbGpPWpGaD
Dipivefrin—ADRB2—GPCR downstream signaling—PIK3CA—hematologic cancer	1.4e-05	5.66e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—TSC2—hematologic cancer	1.4e-05	5.65e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Metabolism—PIK3CB—hematologic cancer	1.4e-05	5.63e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Hemostasis—AKT1—hematologic cancer	1.4e-05	5.62e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—FN1—hematologic cancer	1.39e-05	5.61e-05	CbGpPWpGaD
Dipivefrin—BCHE—Metabolism—PTEN—hematologic cancer	1.39e-05	5.6e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling by GPCR—KRAS—hematologic cancer	1.39e-05	5.59e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—BAD—hematologic cancer	1.38e-05	5.55e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—NFKBIA—hematologic cancer	1.38e-05	5.55e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—FGF2—hematologic cancer	1.38e-05	5.54e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Metabolism—CREBBP—hematologic cancer	1.37e-05	5.54e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—NOTCH1—hematologic cancer	1.36e-05	5.49e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—FGF2—hematologic cancer	1.36e-05	5.47e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—PIK3R1—hematologic cancer	1.36e-05	5.46e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—MAP2K1—hematologic cancer	1.35e-05	5.44e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—FGFR3—hematologic cancer	1.35e-05	5.44e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—PIK3CD—hematologic cancer	1.34e-05	5.4e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—PIK3R1—hematologic cancer	1.34e-05	5.39e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—MAPK14—hematologic cancer	1.34e-05	5.38e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—CD80—hematologic cancer	1.34e-05	5.38e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—PIK3CG—hematologic cancer	1.33e-05	5.37e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—KIT—hematologic cancer	1.33e-05	5.37e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling by GPCR—NRAS—hematologic cancer	1.33e-05	5.37e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—GPCR downstream signaling—PIK3CA—hematologic cancer	1.33e-05	5.35e-05	CbGpPWpGaD
Dipivefrin—BCHE—Metabolism—EP300—hematologic cancer	1.33e-05	5.34e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—JAK2—hematologic cancer	1.32e-05	5.31e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling by GPCR—KRAS—hematologic cancer	1.31e-05	5.29e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—ESR1—hematologic cancer	1.31e-05	5.28e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—PTPN11—hematologic cancer	1.31e-05	5.28e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Metabolism—PIK3CD—hematologic cancer	1.3e-05	5.25e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—JAK2—hematologic cancer	1.3e-05	5.24e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—FN1—hematologic cancer	1.3e-05	5.22e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling by GPCR—PIK3CA—hematologic cancer	1.29e-05	5.2e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—MDM2—hematologic cancer	1.29e-05	5.18e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Metabolism—ALB—hematologic cancer	1.29e-05	5.18e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—FGF2—hematologic cancer	1.28e-05	5.17e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—BAD—hematologic cancer	1.28e-05	5.15e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—NFKBIA—hematologic cancer	1.28e-05	5.15e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling by GPCR—MAPK3—hematologic cancer	1.28e-05	5.15e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling by GPCR—PIK3CA—hematologic cancer	1.28e-05	5.14e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—MDM2—hematologic cancer	1.27e-05	5.12e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—CREB1—hematologic cancer	1.27e-05	5.11e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—NOTCH1—hematologic cancer	1.27e-05	5.1e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—PIK3R1—hematologic cancer	1.27e-05	5.1e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—BRAF—hematologic cancer	1.25e-05	5.05e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—MTOR—hematologic cancer	1.25e-05	5.04e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—PIK3CB—hematologic cancer	1.25e-05	5.04e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—CCL2—hematologic cancer	1.24e-05	5e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—CD80—hematologic cancer	1.24e-05	5e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—PIK3CG—hematologic cancer	1.24e-05	4.99e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—KIT—hematologic cancer	1.24e-05	4.99e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling by GPCR—NRAS—hematologic cancer	1.24e-05	4.99e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—IL6R—hematologic cancer	1.24e-05	4.99e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—CREBBP—hematologic cancer	1.24e-05	4.98e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—PIK3CB—hematologic cancer	1.24e-05	4.98e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—MTOR—hematologic cancer	1.24e-05	4.98e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—JAK2—hematologic cancer	1.23e-05	4.96e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Metabolism—PIK3R1—hematologic cancer	1.23e-05	4.96e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—PTPN11—hematologic cancer	1.22e-05	4.9e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Metabolism—PTEN—hematologic cancer	1.21e-05	4.87e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling by GPCR—PIK3CA—hematologic cancer	1.21e-05	4.86e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—MDM2—hematologic cancer	1.2e-05	4.84e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling by GPCR—HRAS—hematologic cancer	1.2e-05	4.81e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling by GPCR—MAPK3—hematologic cancer	1.19e-05	4.78e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—MAP2K1—hematologic cancer	1.18e-05	4.75e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling by GPCR—HRAS—hematologic cancer	1.18e-05	4.75e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—CREB1—hematologic cancer	1.18e-05	4.75e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—CDKN1B—hematologic cancer	1.18e-05	4.73e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—PIK3CD—hematologic cancer	1.17e-05	4.72e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—PIK3CB—hematologic cancer	1.17e-05	4.71e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—MTOR—hematologic cancer	1.17e-05	4.71e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—BRAF—hematologic cancer	1.17e-05	4.69e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—GPCR downstream signaling—AKT1—hematologic cancer	1.16e-05	4.68e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—GPCR downstream signaling—PIK3CA—hematologic cancer	1.16e-05	4.68e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—CDKN1B—hematologic cancer	1.16e-05	4.67e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—CCL2—hematologic cancer	1.15e-05	4.65e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Metabolism—EP300—hematologic cancer	1.15e-05	4.64e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—CASP3—hematologic cancer	1.15e-05	4.64e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—IL6R—hematologic cancer	1.15e-05	4.64e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—IL2—hematologic cancer	1.15e-05	4.63e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—CREBBP—hematologic cancer	1.15e-05	4.63e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling by GPCR—KRAS—hematologic cancer	1.15e-05	4.62e-05	CbGpPWpGaD
Dipivefrin—ADRB2—GPCR downstream signaling—AKT1—hematologic cancer	1.15e-05	4.62e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling by GPCR—IL6—hematologic cancer	1.14e-05	4.61e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—CASP3—hematologic cancer	1.14e-05	4.58e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Metabolism—PIK3CB—hematologic cancer	1.14e-05	4.57e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—IL2—hematologic cancer	1.14e-05	4.57e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling by GPCR—IL6—hematologic cancer	1.13e-05	4.55e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—FGF2—hematologic cancer	1.12e-05	4.52e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—CCND1—hematologic cancer	1.12e-05	4.51e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—JUN—hematologic cancer	1.12e-05	4.5e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling by GPCR—HRAS—hematologic cancer	1.12e-05	4.5e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—PIK3R1—hematologic cancer	1.11e-05	4.46e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—CCND1—hematologic cancer	1.11e-05	4.46e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—JUN—hematologic cancer	1.1e-05	4.45e-05	CbGpPWpGaD
Dipivefrin—ACHE—Metabolism—PIK3CA—hematologic cancer	1.1e-05	4.43e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—CDKN1B—hematologic cancer	1.1e-05	4.42e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—MAP2K1—hematologic cancer	1.1e-05	4.42e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—PIK3CD—hematologic cancer	1.09e-05	4.39e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—GPCR downstream signaling—AKT1—hematologic cancer	1.09e-05	4.37e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—CDKN1A—hematologic cancer	1.08e-05	4.37e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—PTEN—hematologic cancer	1.08e-05	4.36e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—GPCR downstream signaling—PIK3CA—hematologic cancer	1.08e-05	4.35e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—JAK2—hematologic cancer	1.08e-05	4.33e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—CASP3—hematologic cancer	1.08e-05	4.33e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—IL2—hematologic cancer	1.07e-05	4.32e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—CDKN1A—hematologic cancer	1.07e-05	4.31e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling by GPCR—IL6—hematologic cancer	1.07e-05	4.3e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—PTEN—hematologic cancer	1.07e-05	4.3e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling by GPCR—KRAS—hematologic cancer	1.07e-05	4.3e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—MAPK8—hematologic cancer	1.06e-05	4.26e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling by GPCR—AKT1—hematologic cancer	1.06e-05	4.25e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling by GPCR—PIK3CA—hematologic cancer	1.06e-05	4.25e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—MDM2—hematologic cancer	1.05e-05	4.23e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—CCND1—hematologic cancer	1.05e-05	4.22e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—MAPK8—hematologic cancer	1.04e-05	4.21e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—JUN—hematologic cancer	1.04e-05	4.21e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—FGF2—hematologic cancer	1.04e-05	4.2e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling by GPCR—AKT1—hematologic cancer	1.04e-05	4.2e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—EP300—hematologic cancer	1.03e-05	4.15e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—PIK3R1—hematologic cancer	1.03e-05	4.14e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—PIK3CB—hematologic cancer	1.02e-05	4.12e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—MTOR—hematologic cancer	1.02e-05	4.12e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—EP300—hematologic cancer	1.02e-05	4.1e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—CDKN1A—hematologic cancer	1.01e-05	4.08e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—PTEN—hematologic cancer	1.01e-05	4.07e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—SRC—hematologic cancer	1e-05	4.04e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—JAK2—hematologic cancer	1e-05	4.03e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—SRC—hematologic cancer	9.91e-06	3.99e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—MAPK8—hematologic cancer	9.89e-06	3.98e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling by GPCR—AKT1—hematologic cancer	9.86e-06	3.97e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Metabolism—PTEN—hematologic cancer	9.82e-06	3.95e-05	CbGpPWpGaD
Dipivefrin—BCHE—Metabolism—PIK3CA—hematologic cancer	9.82e-06	3.95e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling by GPCR—PIK3CA—hematologic cancer	9.8e-06	3.95e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—VEGFA—hematologic cancer	9.77e-06	3.93e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—MDM2—hematologic cancer	9.76e-06	3.93e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling by GPCR—HRAS—hematologic cancer	9.76e-06	3.93e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—STAT3—hematologic cancer	9.68e-06	3.9e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—NRAS—hematologic cancer	9.65e-06	3.89e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—VEGFA—hematologic cancer	9.65e-06	3.88e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—EP300—hematologic cancer	9.64e-06	3.88e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—CDKN1B—hematologic cancer	9.6e-06	3.86e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—STAT3—hematologic cancer	9.55e-06	3.85e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—NRAS—hematologic cancer	9.53e-06	3.84e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—PIK3CB—hematologic cancer	9.5e-06	3.83e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—MTOR—hematologic cancer	9.5e-06	3.83e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—GPCR downstream signaling—AKT1—hematologic cancer	9.49e-06	3.82e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—CASP3—hematologic cancer	9.4e-06	3.79e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—IL2—hematologic cancer	9.39e-06	3.78e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—SRC—hematologic cancer	9.37e-06	3.77e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Metabolism—EP300—hematologic cancer	9.36e-06	3.77e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling by GPCR—IL6—hematologic cancer	9.34e-06	3.76e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—MAPK3—hematologic cancer	9.24e-06	3.72e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—CCND1—hematologic cancer	9.15e-06	3.69e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—JUN—hematologic cancer	9.13e-06	3.68e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—VEGFA—hematologic cancer	9.13e-06	3.68e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—MAPK3—hematologic cancer	9.13e-06	3.67e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling by GPCR—HRAS—hematologic cancer	9.07e-06	3.65e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—STAT3—hematologic cancer	9.04e-06	3.64e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—NRAS—hematologic cancer	9.02e-06	3.63e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—MYC—hematologic cancer	8.99e-06	3.62e-05	CbGpPWpGaD
Dipivefrin—ACHE—Metabolism—AKT1—hematologic cancer	8.99e-06	3.62e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—TGFB1—hematologic cancer	8.97e-06	3.61e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—CDKN1B—hematologic cancer	8.92e-06	3.59e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—MYC—hematologic cancer	8.88e-06	3.57e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—CDKN1A—hematologic cancer	8.86e-06	3.57e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—TGFB1—hematologic cancer	8.86e-06	3.57e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—PTEN—hematologic cancer	8.84e-06	3.56e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—GPCR downstream signaling—AKT1—hematologic cancer	8.82e-06	3.55e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—CASP3—hematologic cancer	8.74e-06	3.52e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—IL2—hematologic cancer	8.72e-06	3.51e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling by GPCR—IL6—hematologic cancer	8.68e-06	3.5e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—MAPK8—hematologic cancer	8.64e-06	3.48e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—MAPK3—hematologic cancer	8.64e-06	3.48e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling by GPCR—AKT1—hematologic cancer	8.62e-06	3.47e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Metabolism—PIK3CA—hematologic cancer	8.53e-06	3.43e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—CCND1—hematologic cancer	8.51e-06	3.42e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—JUN—hematologic cancer	8.49e-06	3.42e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—EP300—hematologic cancer	8.43e-06	3.39e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—MYC—hematologic cancer	8.4e-06	3.38e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—TGFB1—hematologic cancer	8.38e-06	3.37e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—KRAS—hematologic cancer	8.31e-06	3.35e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—CDKN1A—hematologic cancer	8.23e-06	3.31e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—PTEN—hematologic cancer	8.21e-06	3.31e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—KRAS—hematologic cancer	8.2e-06	3.3e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—SRC—hematologic cancer	8.19e-06	3.3e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—MAPK8—hematologic cancer	8.03e-06	3.23e-05	CbGpPWpGaD
Dipivefrin—BCHE—Metabolism—AKT1—hematologic cancer	8.02e-06	3.23e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling by GPCR—AKT1—hematologic cancer	8.01e-06	3.22e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—VEGFA—hematologic cancer	7.98e-06	3.21e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—STAT3—hematologic cancer	7.9e-06	3.18e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—NRAS—hematologic cancer	7.88e-06	3.17e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—EP300—hematologic cancer	7.83e-06	3.15e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—KRAS—hematologic cancer	7.76e-06	3.12e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—PIK3CA—hematologic cancer	7.63e-06	3.07e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—SRC—hematologic cancer	7.61e-06	3.07e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—MAPK3—hematologic cancer	7.55e-06	3.04e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—PIK3CA—hematologic cancer	7.54e-06	3.03e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—VEGFA—hematologic cancer	7.41e-06	2.99e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—TP53—hematologic cancer	7.38e-06	2.97e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—MYC—hematologic cancer	7.34e-06	2.96e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—STAT3—hematologic cancer	7.34e-06	2.96e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—TGFB1—hematologic cancer	7.32e-06	2.95e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—NRAS—hematologic cancer	7.32e-06	2.95e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—TP53—hematologic cancer	7.29e-06	2.94e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—PIK3CA—hematologic cancer	7.13e-06	2.87e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—HRAS—hematologic cancer	7.06e-06	2.84e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—MAPK3—hematologic cancer	7.01e-06	2.82e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—HRAS—hematologic cancer	6.97e-06	2.81e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Metabolism—AKT1—hematologic cancer	6.97e-06	2.8e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Metabolism—PIK3CA—hematologic cancer	6.93e-06	2.79e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—TP53—hematologic cancer	6.9e-06	2.78e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—MYC—hematologic cancer	6.82e-06	2.75e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—TGFB1—hematologic cancer	6.81e-06	2.74e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—KRAS—hematologic cancer	6.78e-06	2.73e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—IL6—hematologic cancer	6.76e-06	2.72e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—IL6—hematologic cancer	6.67e-06	2.69e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—HRAS—hematologic cancer	6.6e-06	2.66e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—IL6—hematologic cancer	6.31e-06	2.54e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—KRAS—hematologic cancer	6.3e-06	2.54e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—AKT1—hematologic cancer	6.24e-06	2.51e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—PIK3CA—hematologic cancer	6.23e-06	2.51e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—AKT1—hematologic cancer	6.16e-06	2.48e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—TP53—hematologic cancer	6.03e-06	2.43e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—AKT1—hematologic cancer	5.82e-06	2.35e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—PIK3CA—hematologic cancer	5.79e-06	2.33e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—HRAS—hematologic cancer	5.77e-06	2.32e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Metabolism—AKT1—hematologic cancer	5.66e-06	2.28e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—TP53—hematologic cancer	5.6e-06	2.26e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—IL6—hematologic cancer	5.52e-06	2.22e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—HRAS—hematologic cancer	5.36e-06	2.16e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—IL6—hematologic cancer	5.13e-06	2.06e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—AKT1—hematologic cancer	5.09e-06	2.05e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—AKT1—hematologic cancer	4.73e-06	1.9e-05	CbGpPWpGaD
